Acesis Holdings Corpの株価・株式情報

Acesis Holdings Corp is a United States-based company. The Company operates as pre-phase I (first-in-man (FIM) clinical, biotechnology company focused on men’s health. The Company develops treatments for low testosterone levels in males (Low-T) known as T-deficiency or male hypogonadism. Its business model is to develop non-steroid product candidates that transform the treatment of men with Low-T. The Company’s lead peptide, ACE-167, has been designed to act through a molecular mechanism to induce the Leydi